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INTRODUCTION
Pneumonia (P) is defined as an acute illness with cough and
at least one of the following: new focal chest signs, fever
for longer than four days or dyspnoea/tachypnoea, without
other obvious cause, and radiographic evidence of lung
shadowing that is likely to be new (File, 2003). The overall
incidence of community-aquired P (CAP) in general prac-
tice in Europe is reported to range between 1.7 and 11.6
cases per 1000 people per year in adults. In the European
Union (EU), about 3 370 000 cases are expected annually.
Hospitalisation rates differ widely between European coun-
tries, ranging from 20–50%, meaning that there are about 1
million hospital admissions for CAP per year in the EU
(Welte et al., 2012). The 90-day mortality rate in the P pa-
tient population may reach 14%; post-hospitalisation mor-
tality is still considerably high within a year after discharge,
in comparison to the general population and to patients hos-
pitalised for other reasons (Wunderink and Waterer, 2014),
However, mortality does not seem to be related to antibiotic
resistance (Frei et al., 2010). CAP is associated with a sig-
nificant increase in the risk of cardiovascular events and
death from cardiac causes.
Rapid and precise diagnosis of CAP is still a relevant prob-
lem and there is no general accepted biomarker to confirm
the diagnosis and to evaluate its severity to guide manage-
ment. Inflammatory markers have different diagnostic cut-
offs; their specificity and sensitivity remain insecure, and
only a few of these have been validated for clinical use
(Nickler et al., 2016). An ideal biomarker for CAP diagno-
sis should allow rapid diagnosis, have prognostic value
and facilitate therapeutic decision making. We suggest that
future clinical studies need to consider biomarkers of oxida-
tive stress (OS), which are objectively measured and evalu-
ated as indicators of normal biological processes, patho-
genic processes and pharmacologic responses to therapeutic
intervention.
Increased oxidative/nitrosative stress generally describes a
condition in which cellular antioxidant (AO) defenses are
inadequate to completely inactivate the reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS) generated,
because of their excessive production, loss of AO defenses,
or both. OS is now recognised to be a common mediator of
many acute and chronic diseases and even of the normal ag-
ing process (Nathan and Cunningham-Bussel, 2013; Schaur
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The paper presents information on pneumonia (P) patients with features of oxidative stress (OS).
Identifying features of OS in patients with P is of interest not only for diagnosis, but also for moni-
toring of treatment efficiency. We recruited 73 patients with community-acquired P (CAP), previ-
ously healthy adults, both males and females with mean age of 68.0 ± 15.2, hospitalised, and 61
healthy control patients matched for age. For quantitative evaluation of lipid peroxidation in CAP
patients, the levels of aldehydic lipid peroxidation products like malondialdehyde (MDA) and 4-
hydroxynon-2-enal (HNE) were quantified. Furthermore, concentrations of reduced glutathione
(GSH) and several antioxidant enzymes and selenium in plasma were determined. In CAP pa-
tients, decreased levels of GSH and plasma selenium were observed. Plasma levels of MDA, and
HNE did significantly differ between patient and control groups. We also noted reduced activity of
antioxidant enzymes, namely, glutation peroxidase and superoxide dismutase. Low antioxidant
enzymes activity was associated with a more severe CAP pattern. Both GSH and antioxidant en-
zymes may serve as markers for inflammation-related OS in CAP patients, and measurement of
these biomarkers may be a valid indentifier for its management.
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et al., 2015;). A major consequence of OS is a variety of
cellular responses through generation of secondary reactive
species that eventually activate cell death by necrosis or
apoptosis. Numerous studies support the idea that the OS
pattern is disease-specific (Dalle-Donne et al., 2006; Wat-
son, 2014; Ursini et al., 2016).
The airway epithelium is subject to oxidative damage from
both exogenous oxidants (cigarette smoke, pollutants) and
endogenous agents (phagocytes). It is accepted widely that
airway infection promotes activation and recruitment of
phagocytic cells in the lungs. OS as a component of patho-
genesis is featured in several lung pathologies — P, alveoli-
tis, mucoviscidosis, chronic obstructive pulmonary disease,
bronchial asthma, idiopathic pulmonary fibrosis, and acute
respiratory distress syndrome (Barnes, 1990). Lung tissue
contains large amounts of non-saturated fatty acids, which
are a substrate for lipid peroxidation (LP). Oxidants that
form during smoking act on the lungs directly. Previous
study of AO dynamics showed that gamma-glutamyl-
cysteine synthetase (gamma-GCS) mRNA is distorted in
smoking patient airway epithelium cells (Taivans et al.,
2001).
OS contributes significantly to inflammatory pathology of
the lung and has important consequences in the patho-
genesis of CAP, including oxidative inactivation of anti-
proteases and surfactants, mucus hypersecretion, membrane
LP, alveolar epithelial injury, remodeling of extracellular
matrix, and apoptosis. The distribution and effects of OS, as
well as information regarding the nature of the ROS/RNS,
may be gleaned from the analysis of discrete biomarkers of
oxidative/nitrosative stress. LP generates plenty of rela-
tively stable decomposition end products, mainly ,-unsat-
urated reactive aldehydes, such as malondialdehyde (MDA)
and 4hydroxy-2-nonenal (HNE), which can then be mea-
sured in plasma and urine as an indirect index of OS. MDA
is one of the most commonly reported biomarkers of LP in
clinical studies. Nevertheless, the most relevant product of
LP, when lipid hydroperoxides are decomposed, seems to be
HNE. HNE may be viewed as a signal transducer of chronic
conditions, and authors have recommended to study HNE in
various processes (Poli et al., 2008, Ursini et al., 2016).
Compared with free radicals (aldehydes), MDA/HNE is
rather stable and exit from cells to several destinations. A
negative association between HNE concentrations in pul-
monary and airway epithelium was onserved in a study on
neutrophils and lung function (FEV1) in chronic obstructive
pulmonary disease patients (Rahman et al., 2002).
The lung, like many other tissues, has a range of AO
defences, which help to maintain a balanced redox status
(Rahman et al., 2006). The AOs are present intracellularly
in vascular and extracellular respiratory tract lining fluid
(RTLF) compartments. Glutathione peroxidases (GPx), also
known as selenoproteins, are a family of AO enzymes-
selenoproteins expressed by endothelial cells. These en-
zymes reduce particularly toxic hydroperoxides. GPx is es-
pecially important in reducing the production of inflamma-
tory prostaglandins and leucotrienås. This enzyme assumes
a critical role in protecting against free-radical and oxida-
tive damage in lungs. The activity of GPxs largely depends
on selenium (Se), due to its presence at the active site of
these enzymes (Brigelius-Flohe and Maiorino, 2013). Se de-
ficiency has often been often reported in Latvia, due to low
concentrations in food grown and consumed in the area. A
protective effect of Se against LP has been observed and a
possible mechanism of action through GPx has been pro-
posed (Voitsekhovskaia et al., 2007). In cases of Se defi-
ciency and with the resulting impaired function of GPx’s,
destructive hydrogen peroxide breaks down into even more
dangerous hydroxyl radicals that damage cell membranes
and cell DNA, eventually leading to OS (Rayman, 2012).
Glutathione (GSH) is a frequently occuring tripeptide thiol
and acts as a vital intra- and extracellular protection AO
against oxidative/nitrosative stresses, interceding the pro-
inflammatory processes in the lungs (Kelly, 1999; Rahman
and MacNee, 2000). Reduction of GSH of respiratory tract
lining fluid is severe, and studies have shown that the RTLF
GSH pool plays a role in respiratory protection (Cantin et
al., 1989). The rate-limiting enzyme in GSH synthesis is
gamma-GCS. The human gamma-GCS heavy and light sub-
units are regulated by activator protein-1 and AO response
elements and are modulated by oxidants, phenolic AOs,
growth factors, and inflammatory and anti-inflammatory
agents in lung cells (Rahman and MacNee, 2000). GPx4 ca-
talyses lipid peroxide banding by GSH; this reaction occurs
at the selenocysteine (Sec) within the catalytic center of
GPx4. The active selenol -SeH is oxidised by peroxides to
selenenic acid -SeOH during the catalytic cycle of GPx4,
which is then reduced with GSH to an intermediate seleno-
disulfide (Yoo et al., 2010). The resulting concentrations of
GSH depend on GSH oxidation by several hydroperoxides,
GSH conjugation to electrophiles and participation in pro-
tein folding, and export and import of GSH and its
compartmental amino acids (particulary Sec). Along the
scavenger pathway, Sec is employed by gamma-glutamyl
transferase to bypass glutamate cysteine ligase (Ursini et
al., 2016).
Changes in GSH metabolism of the alveoli and the lungs
are a main feature of several inflammatory lung diseases,
notably, asthma, cystic fibrosis, acute respiratory distress
syndrome and idiopathic pulmonary fibrosis (Rahman and
MacNee, 2000).
Superoxide dismutase (SOD) appears to be another impor-
tant AO defense against ROS. SOD belongs to a family of
enzymes that function to efficiently catalyse the dismutation
of superoxide anions. Evidence supports the notion that lack
of SOD contributes to impaired angiogenesis, vascular ab-
normality, increased vasoconstriction and endothelial dys-
function (Groleau et al, 2010).
The aim of the study was to evaluate oxidative stress pa-
rameters in patients with pneumonia.
MATERIALS AND METHODS
The prospective and randomised study included patients
with radiologically approved CAP: 73 previously healthy
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adults, 31 male and 42 female, with mean age 68.0 ± 15.2,
hospitalised in the Pulmonology and Allergology Depart-
ment of Pauls Stradiòð Clinical University Hospital (Rîga,
Latvia) from 1 January 2015 to 31 December 2015. The
clinical diagnosis was based on CAP symptoms (acute on-
set, increased body temperature, and cough with/without
sputum) and auscultative findings. Radiologic approval of
diagnosis was obtained from the first chest x-ray or com-
puter tomography scan. In addition, 61 healthy age-matched
controls were recruited: 4 males and 57 females. Past his-
tory of smoking was considered as well.
To assess CAP severety, the Pneumonia Severety Index
(PSI) was applied (Fine et al., 1997). PSI assigns points
based on age and presence of coexisting disease, abnormal
physical findings (such as respiratory rate  30 or tempera-
ture  40 degrees C), and abnormal laboratory findings
(such as pH .35, blood urea nitrogen concentration30  mg
dl-1 or sodium concentration < 130 mmol l-1). Risk using a
score of I–V was estimated based on percentage risk of
death within 30 days.
The study protocol, the agreement and participation proto-
cols were in accordance with the Declaration of Helsinki of
Humanity in Medicine and were approved by the Commis-
sion on Ethics of Rîga Stradiòð University, Latvia (RSU).
There was no conflict of interest. All laboratory tests were
performed in the Biochemical Laboratory of RSU (EU cer-
tified).
Blood samples were collected after overnight fast (~10–12
hours). Fresh venous blood samples were collected into vac-
uum tubes (BD VacutainerTM) containing anticoagulant
lithium heparin and centrifuged at 1600 g for 10 minutes
at 4 °C. The plasma and buffy coat were separated. Chem-
ically pure reactants (analytical grade) from Merck
(Darmstadt, Germany), H2O2 from Sigma-Aldrich (St. Luis,
USA) were used; water was double distilled (distillation ap-
paratus from Sanyo Gallenkamp PLC, Leicester, UK).
Inter-laboratory quality control was conducted using two
standards — Se AAS solution (Aldrich, USA, Cat No. 24,
792-8) and Seronorm TE Serum Level I (from Synlab diag-
nostic GmbH, Germany) for the Seronorm™ Trace Ele-
ments-Controls Programme; external quality assessment
services were implemented by Labquality Oy, Finland.
Variables were presented as mean ± standard deviation or
median (interquartile range). Mann-Whitney U-tests were
used to compare CAP and healthy control groups. SPSS for
Windows version 23.0 (USA) was used for statistical analy-
ses. Statistical significance of mean values was evaluated by
means of the paired-samples T-Test. A p value < 0.05 was
considered as statistically significant in all analyses. Interre-
lationship between parameters was evaluated by the Wil-
coxon correlation coefficient.
Plasma Se was determined fluorimetrically (Alfthan, 1984).
Activity of GPx was determined in heparinised whole blood
using commercial tests manufactured by Randox Labora-
tories (UK, Antrium) in a RX Daytona analyser. The assay
products were measured by the method of Paglia and Valen-
tine (Paglia and Valentine, 1967).
Plasma MDA was measured by means of high-performance
liquid chromatography (Esterbauer and Cheesman, 1990).
The method allowed to distinguish between separate MDA
and MDA together with HNE.
Cu, Zn- SOD activity was determined according to the
method of Woolliams et al. (Woolliams et al., 1983) using a
RANDOX (RANSOD) kit.
GSH was determined by the method of Beutler et al. (Beut-
ler et al., 1963).
RESULTS
The study included 73 patients with mean age 68.0 ± 15.2:
31 males (42.5%) and 42 females (57.5%). PSI was deter-
mined in all 73 patients (100%).
Mean values for PSI scores and OS parameters were as fol-
lows (Tables 1–3, Fig. 1):
Lower levels of GSH and plasma selenium were observed
in CAP vs control groups (Tables 1, 2). We also noted re-
duced activity of some antioxidant enzymes (GPx and
SOD) in CAP patients vs healthy controls (Tables 1, 2). A
low antioxidant enzymes activity was associated with a
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T a b l e 1








Age 67.0 14.0 69.7 17.6
Pneumonia Severity Index 99.7 28.8 111.3 104.4
GSH, mmol/l 1.11 0.20 1.12 0.24
Se, mg/l 70.28 18.38 64.41 23.04
SOD, U/g Hb 1580 343 1709 263
GPx, U/ml 6070 1885 6017 1783
MDA, µM 1.44 .38 1.50 45
HNE, µM 2.56 1.19 2.56 1.15
MDA+HNE, µM 4.01 1.10 4.06 1.12
T a b l e 2
BIOMARKER LEVELS AND PSI IN THE CONTROL GROUP
Parameter Mean Standard Deviation
Age 68.3 15.4
GSH, mmol/l 1.20 0.16
Se, mg/l 74.61 18.41
SOD, U/g Hb 1663 169.64
GPx, U/ml 7719 1741
MDA, µM 1.14 0.55
HNE, µM 2.92 1.26
MDA+HNE, µM 4.06 0.91
more severe CAP pattern (Table 3). There was negative cor-
relation between GPx and PSI as well as between SOD and
PSI in male patients (Fig. 1). We assume that antioxidant
enzymes were significantly reduced in this patient group
due to the high proportion of smokers in the group.
We did not find significant elevation of HNE and MDA
(Tables 1, 2). Slightly higher levels of MDA/HNE occurred
in all patients, and were obviously elevated in female smok-
ers (Table 3). However, in a few patients the MDA/HNE
level was surprisingly low, resulting in mean values that
were at normal levels, i.e. comparable to healthy controls.
DISCUSSION
We recommend that GPx, SOD, and GSH levels are consid-
ered in evaluation of CAP severity. OS parameters provide
additional value in CAP severity evaluation together with
well-known inflammatory markers (C-reactive protein, leu-
cocytes, etc). The combination of several biomarkers re-
flecting different pathophysiological pathways might have
potential in improving management of CAP in the future.
The most controversial seem to be the MDA/HNE results.
We expected high MDA/HNE levels in cases of OS in CAP.
Numerous patients had extremely low MDA/HNE levels,
demonstrating a very severe CAP pattern and need for intra-
venous fluid. Plasma dilution might have affected
MDA/HNE results. GPx, SOD, GSH were tested using
erythrocyte substrate, and thus no effect of intravenous fluid
was noted.
Lower levels of GSH in CAP patients have been observed
also in other studies (Kelly, 1999; Rahman and MacNee,
2000; Castillo R. et al., 2013) and suggest that deficit of
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T a b l e 3





no yes no yes
mean stand. deviat. mean stand. deviat. mean stand. deviat. mean stand. deviat
Age 71.3 14.4 64.8 14.8 73.9 17.4 61.3 15.6
PSI 108.3 28.0 95.2 33.8 124.4 149.4 95.0 43.8
GSH, mmol/l 1.15 0.18 1.12 0.24 1.09 0.23 1.16 0.37
Se, mg/l 88.91 52.15 71.47 25.28 52.65 15.76
SOD, U/g Hb 1803 260 1546 335 1734 274 1747 191
GPx, U/ml 6682 1709 5821 2105 6264 1866 3966 454
MDA, µM 1.74 0.23 1.32 0.40 1.57 0.47 1.43 0.42
HNE, µM 3.00 1.50 2.61 1.40 2.12 0.91 4.14 0.32
MDA+HNE, µM 4.74 1.28 3.93 1.24 3.69 0.98 5.57 37
Fig. 1. Mean GPx and Pneumonia Severity Index in male patients.
GSH might predispose to pulmonary inflammation. The
protective role of GSH in regard to the lower respiratory
tract has been suggested; hence, use of GSH inhalations
might be beneficial for cystic fibrosis treatment (Prousky,
2008; Day, 2005). In our study, the relatively small sample
size of the patientcohort was a limitation. We nevertheless
believe that the data obtained are meaningful and should
prompt further large-scale investigations. There is evidence
of systemic OS and systemic inflammation in CAP. We be-
lieve that lower GSH and antioxidant enzyme activity are
features of CAP manifestation and that measurement of
these biomarkers (GPx, SOD, GSH) in blood can be a valid
index in the management of CAP to assess the status of OS,
inflammation, and to predict CAP severity and/or complica-
tions. We would like to emphasise once again that in clini-
cal practice, there is a risk of underestimating the severity of
the patient with CAP using standard criteria, making it nec-
essary to continue investigations regarding the use of bio-
logical markers of adverse clinical outcomes.
Considering the study results we conclude, that:
1. Se deficiency in the CAP patients, inhabitants of Latvia,
was shown: average Se plasma level in CAP patients was
66.01 mcg/l, in healthy controls: 74.61 mcg/l. The mean
level in Europe is 80–120 mcg/l (Rayman, 2012). The de-
gree of Se deficiency in CAP patients seems to be compara-
ble to that of the entire population.
2. Decreased activity of both GPx and SOD was associated
with a significant decrease of GSH concentration, indicating
rapid consumption of GSH via GPx reaction. Decreased
SOD and GPx activity was associated with a more severe
CAP pattern.
3. GSH, GPx and SOD can be used as markers for
inflammation-related OS in CAP patients and measurement
of these biomarkers can be a valid index in CAP severity as-
sessment and management.
4. Regarding MDA/HNE level: we believe that special at-
tention should be paid to the procedure of blood sample col-
lection (to avoid collection after intravenous fluid admini-
stration). Determination of MDA/HNE in erythrocytes, not
plasma, would be prefered.
The views expressed in this article are those of the authors
and do not reflect the official policy or position of the Lat-
vian Ministry of Health or any of the institutions with which
the authors are affiliated. All authors read and approved the
final manuscript.
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BIOMARÍIERI SABIEDRÎBÂ IEGÛTAS PNEIMONIJAS GAITAS NOVÇRTÇÐANAI
Rakstâ apkopota informâcija par oksidatîvâ stresa (OS) râdîtâjiem pacientiem ar pneimoniju (P). OS pazîmju noteikðana pacientiem ar P ir
svarîga ne tikai diagnostiskâ procesa vadîðanai, bet arî terapijas efektivitâtes novçrtçðanâ. Mçs atlasîjâm 73 pacientus ar sabiedrîbâ iegûto
pneimoniju (SIP), iepriekð veselus pieauguðos, vîrieðus un sievietes ar vidçjo vecumu 68 gadi, kas bija stacionçti nodaïâ, un 61 kontroles
pacientu atbilstoðâ vecuma. Kvantitatîvai lipîdu peroksidâcijas novçrtçðanai SIP pacientu vidû noteicâm aldehîdu grupas peroksidâcijas
vielas — malondialdehîdu (MDA) un 4-hidroksinon-2-enal (HNE). Pçtîjuma laikâ tika noteikta glutationa (GSH) un citu antioksidantu
enzîmu aktivitâte, kâ arî plazmas selçna daudzums. SIP pacientu vidû novçrojâm samazinâtu GSH un selçna daudzumu, kâ arî
antioksidatîvo enzîmu, îpaði glutationa peroksidâzes un superoksîddismutâzes aktivitâti. Plazmas MDA un HNE rezultâti bija pretrunîgi,
salîdzinot ar kontroles grupu. Mazinâts antioksidatîvo enzîmu skaits tika saistîts ar smagâku SIP klînisko ainu, salîdzinot ar kontroli.
Aprakstîtie novçrojumi bija izteiktâki pacientu smçíçtâju vidû. GSH un antioksidatîvo enzîmu aktivitâte var kalpot kâ biomaríieri pie
iekaisuma mediçtâ OS pacientiem ar SIP, un ðos parametrus iespçjams pielietot slimîbas vadîðanâ.
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